JP2014511866A5 - - Google Patents

Download PDF

Info

Publication number
JP2014511866A5
JP2014511866A5 JP2014504086A JP2014504086A JP2014511866A5 JP 2014511866 A5 JP2014511866 A5 JP 2014511866A5 JP 2014504086 A JP2014504086 A JP 2014504086A JP 2014504086 A JP2014504086 A JP 2014504086A JP 2014511866 A5 JP2014511866 A5 JP 2014511866A5
Authority
JP
Japan
Prior art keywords
domain
chimeric polypeptide
fragment
par2
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014504086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511866A (ja
JP6225104B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032824 external-priority patent/WO2012139137A2/en
Publication of JP2014511866A publication Critical patent/JP2014511866A/ja
Publication of JP2014511866A5 publication Critical patent/JP2014511866A5/ja
Application granted granted Critical
Publication of JP6225104B2 publication Critical patent/JP6225104B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014504086A 2011-04-08 2012-04-09 ペプデューシンの設計および使用 Expired - Fee Related JP6225104B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473675P 2011-04-08 2011-04-08
US61/473,675 2011-04-08
PCT/US2012/032824 WO2012139137A2 (en) 2011-04-08 2012-04-09 Pepducin design and use

Publications (3)

Publication Number Publication Date
JP2014511866A JP2014511866A (ja) 2014-05-19
JP2014511866A5 true JP2014511866A5 (cg-RX-API-DMAC7.html) 2015-05-28
JP6225104B2 JP6225104B2 (ja) 2017-11-01

Family

ID=46969875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504086A Expired - Fee Related JP6225104B2 (ja) 2011-04-08 2012-04-09 ペプデューシンの設計および使用

Country Status (6)

Country Link
US (1) US10913781B2 (cg-RX-API-DMAC7.html)
EP (2) EP3351641A1 (cg-RX-API-DMAC7.html)
JP (1) JP6225104B2 (cg-RX-API-DMAC7.html)
AU (1) AU2012239880B2 (cg-RX-API-DMAC7.html)
CA (1) CA2832115C (cg-RX-API-DMAC7.html)
WO (1) WO2012139137A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351641A1 (en) 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
CN105517562B (zh) * 2013-04-05 2018-12-28 拜欧马可医药公司 转移抑制剂
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
ES2984663T3 (es) 2015-11-13 2024-10-30 Oasis Pharmaceuticals Llc Moduladores del receptor 2 activados por proteasa
ES2909709T3 (es) * 2016-05-12 2022-05-10 Heptares Therapeutics Ltd Inhibidores del receptor 2 activado por proteasa
AU2020250933A1 (en) 2019-04-05 2021-10-28 Centre Hospitalier Régional Et Universitaire De Brest Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
KR102268589B1 (ko) * 2019-04-29 2021-06-24 사회복지법인 삼성생명공익재단 단백질분해효소 활성 수용체 매개 신호전달 경로의 활성을 이용한 세포외 소포의 고효율 생성능을 갖는 줄기세포의 선별방법
EP4595983A1 (en) * 2024-02-05 2025-08-06 BXTA Nanotherapy Limited Nanoparticles functionalised with a stabilising agent and a targeting agent
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
EP0835928A1 (en) 1996-10-11 1998-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Helicobacter pylori live vaccine
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6815200B1 (en) 1998-02-17 2004-11-09 The Uab Research Foundation Modified adenovirus containing a fiber replacement protein
NZ530277A (en) 1998-04-07 2005-08-26 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
US6562958B1 (en) 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
US6228989B1 (en) * 1998-11-13 2001-05-08 The Regents Of The University Of California Peptide substrates phosphorylated by P21-activated protein kinase
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2001081408A2 (en) * 2000-04-21 2001-11-01 New England Medical Center G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US6773893B1 (en) 2000-04-28 2004-08-10 The Trustees Of Columbia University In The City Of New York Human ABC1 promoter and assays based thereon
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004012681A2 (en) 2002-08-02 2004-02-12 South Alabama Medical Sciences Foundation Cancer vaccines containing epitopes of oncofetal antigen
WO2004022576A2 (en) 2002-09-03 2004-03-18 Children's Hospital Short peptides from the '2nd loop' of 7 transmembrane receptor which selectively modulate signal transduction
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2004067712A2 (en) * 2003-01-22 2004-08-12 Incyte Corporation Intracellular signaling molecules
US7189691B2 (en) 2004-04-01 2007-03-13 The Administrators Of The Tulane Educational Fund Methods and compositions for treating leukemia
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US7319142B1 (en) 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
US8440627B2 (en) 2004-11-04 2013-05-14 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of use
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2007061850A2 (en) 2005-11-17 2007-05-31 Massachusetts Institute Of Technology Methods and systems for generating and evaluating peptides
DK1987178T3 (en) 2006-02-20 2015-04-20 Phylogica Ltd Process for the construction and screening of peptide structure libraries
CA2660286A1 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008144753A2 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
JP4400668B2 (ja) 2007-11-01 2010-01-20 株式会社豊田中央研究所 微小物体が固定化された固相体の製造方法及びその利用
WO2009099580A2 (en) 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
EP2362779A4 (en) 2008-11-04 2013-03-20 Anchor Therapeutics Inc CXCR4 RECEPTOR COMPOUNDS
RU2011122482A (ru) 2008-11-04 2012-12-20 Энкер Терапьютикс, Инк. Apj-рецепторы соединения
US8303962B2 (en) 2009-01-06 2012-11-06 C3 Jian, Inc. Antibacterial and antifungal peptides
US9012723B2 (en) 2009-01-16 2015-04-21 Monsanto Technology Llc Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
JP2012523438A (ja) * 2009-04-10 2012-10-04 タフツ メディカル センター インコーポレイテッド メタロプロテイナーゼ−1(mmp−1)によるpar−1活性化
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP3351641A1 (en) 2011-04-08 2018-07-25 Tufts Medical Center, Inc. Pepducin design and use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof

Similar Documents

Publication Publication Date Title
AU2010202328B2 (en) G Protein Coupled Receptor Agonists and Antagonists and Methods of Use
US10253080B2 (en) Glucagon-like-peptide-2 (GLP-2) analogues
US10092648B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
ES2984663T3 (es) Moduladores del receptor 2 activados por proteasa
BR112015010203B1 (pt) uso de uma composição para a preparação de um medicamento para a prevenção ou o tratamento de diabetes, complicações diabéticas ou diabesidade compreendendo um conjugado analogo da oxintomodulina
JP2011526303A5 (cg-RX-API-DMAC7.html)
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
JP2018537529A5 (cg-RX-API-DMAC7.html)
WO2022238510A1 (en) Therapeutic derivatives of interleukin-22
JP2013535965A5 (cg-RX-API-DMAC7.html)
ES2575517T3 (es) Péptidos de unión a FGF2 y usos de los mismos
AU2020299636A1 (en) Compositions and methods of use
JP2005213160A (ja) Fas作動性アポトーシス調節ペプチドとその用途